Paper39724243
Breaking the resistance: integrative approaches with novel therapeutics against Klebsiella pneumoniae.
Koul V and 5 others. Arch Microbiol, 2024. Cited by 15 papers, by iCite.
Cite this record
ConductScience Library. Breaking the resistance: integrative approaches with novel therapeutics against Klebsiella pneumoniae. Papers, record 39724243. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39724243
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Breaking the resistance: integrative approaches with novel therapeutics against Klebsiella pneumoniae.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anti-Bacterial Agents | Major topic |
| Drug Resistance, Multiple, Bacterial | Major topic |
| Klebsiella Infections | Major topic |
| Klebsiella pneumoniae | Major topic |
| Humans | |
| Biological Products | |
| Drug Discovery | |
| Drug Repositioning |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| CSPS24/RDSF/IIIM/IHP24/03 | CSIR-R&D Seed Fund (RDSF) | PubMed |
Source PubMed
References131
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32201008 | Antimicrobial resistance, mechanisms and its clinical significance. | Dis Mon | 2020 | https://conductscience.org/library/papers/32201008 | PubMed |
| 2 | 33134741 | An exegesis of bacteriophage therapy: An emerging player in the fight against anti-microbial resistance. | AIMS Microbiol | 2020 | https://conductscience.org/library/papers/33134741 | PubMed |
| 3 | 35163939 | Synthesis, Antimicrobial, Anti-Virulence and Anticancer Evaluation of New 5(4H)-Oxazolone-Based Sulfonamides. | Molecules | 2022 | https://conductscience.org/library/papers/35163939 | PubMed |
| 4 | 34276590 | Metabolite Profiling of Malaysian Gracilaria edulis Reveals Eplerenone as Novel Antibacterial Compound for Drug Repurposing Against MDR Bacteria. | Front Microbiol | 2021 | https://conductscience.org/library/papers/34276590 | PubMed |
| 5 | 34476772 | Current Stage in the Development of Klebsiella pneumoniae Vaccines. | Infect Dis Ther | 2021 | https://conductscience.org/library/papers/34476772 | PubMed |
| 6 | 33510482 | Natural products in drug discovery: advances and opportunities. | Nat Rev Drug Discov | 2021 | https://conductscience.org/library/papers/33510482 | PubMed |
| 7 | 35865823 | Isolation and Characterization of vB_kpnM_17-11, a Novel Phage Efficient Against Carbapenem-Resistant Klebsiella pneumoniae. | Front Cell Infect Microbiol | 2022 | https://conductscience.org/library/papers/35865823 | PubMed |
| 8 | 30207815 | Multidrug-resistant Klebsiella pneumoniae: challenges for treatment, prevention and infection control. | Expert Rev Anti Infect Ther | 2018 | https://conductscience.org/library/papers/30207815 | PubMed |
| 9 | 30447360 | Facile green synthesis of silver nanoparticles using Berberis vulgaris leaf and root aqueous extract and its antibacterial activity. | Int J Biol Macromol | 2019 | https://conductscience.org/library/papers/30447360 | PubMed |
| 10 | 30026034 | Cerium oxide nanoparticles as potential antibiotic adjuvant. Effects of CeO2 nanoparticles on bacterial outer membrane permeability. | Biochim Biophys Acta Biomembr | 2018 | https://conductscience.org/library/papers/30026034 | PubMed |
| 11 | 30452654 | Klebsiella pneumoniae infection biology: living to counteract host defences. | FEMS Microbiol Rev | 2019 | https://conductscience.org/library/papers/30452654 | PubMed |
| 12 | 36558132 | Applications of Essential Oils and Plant Extracts in Different Industries. | Molecules | 2022 | https://conductscience.org/library/papers/36558132 | PubMed |
| 13 | 19035777 | Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. | Clin Infect Dis | 2009 | https://conductscience.org/library/papers/19035777 | PubMed |
| 14 | 36978495 | Design and Synthesis of Novel Antimicrobial Agents. | Antibiotics (Basel) | 2023 | https://conductscience.org/library/papers/36978495 | PubMed |
| 15 | 32152527 | Antibiotics in the clinical pipeline in October 2019. | J Antibiot (Tokyo) | 2020 | https://conductscience.org/library/papers/32152527 | PubMed |
| 16 | 37113135 | Synergistic effect and antibiofilm activity of the antimicrobial peptide K11 with conventional antibiotics against multidrug-resistant and extensively drug-resistant Klebsiella pneumoniae. | Front Cell Infect Microbiol | 2023 | https://conductscience.org/library/papers/37113135 | PubMed |
| 17 | 37972089 | Synergistic effect of two antimicrobial peptides, BP203 and MAP-0403 J-2 with conventional antibiotics against colistin-resistant Escherichia coli and Klebsiella pneumoniae clinical isolates. | PLoS One | 2023 | https://conductscience.org/library/papers/37972089 | PubMed |
| 18 | 38953095 | Exploration of Antimicrobial Peptides in the Treatment of Gentamicin-Resistant Klebsiella pneumoniae Infection. | Infect Drug Resist | 2024 | https://conductscience.org/library/papers/38953095 | PubMed |
| 19 | 31114568 | Distinct Roles of Outer Membrane Porins in Antibiotic Resistance and Membrane Integrity in Escherichia coli. | Front Microbiol | 2019 | https://conductscience.org/library/papers/31114568 | PubMed |
| 20 | 31847614 | Antibiotic combination therapy against resistant bacterial infections: synergy, rejuvenation and resistance reduction. | Expert Rev Anti Infect Ther | 2020 | https://conductscience.org/library/papers/31847614 | PubMed |
Cited by5
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 15 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42676813 | Antibiotic resistance in K. pneumoniae: perspectives, challenges, health risks, therapeutic approaches. | Front Microbiol | 2026 | https://conductscience.org/library/papers/42676813 | PubMed |
| 42517888 | Characterization of beddomeilactone amide as bacterial DNA gyrase inhibitor: in vitro evaluation and computational insights. | Med Chem Res | 2026 | https://conductscience.org/library/papers/42517888 | PubMed |
| 42446684 | Discovery of new bioactive secondary metabolites from the stem bark of oroxylum indicum: isolation, structural identification, antimicrobial and cytotoxicity assessment. | Med Chem Res | 2026 | https://conductscience.org/library/papers/42446684 | PubMed |
| 42429828 | N-sulfonylated indole hydrazone hybrid targeting Staphylococcus aureus with compelling antibiofilm and membrane-disrupting properties. | Naunyn Schmiedebergs Arch Pharmacol | 2026 | https://conductscience.org/library/papers/42429828 | PubMed |
| 41849041 | Deciphering the potentiality of Andrographolide derivatives against Pseudomonas aeruginosa: in vitro analysis and mechanistic insights. | World J Microbiol Biotechnol | 2026 | https://conductscience.org/library/papers/41849041 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39724243
GET https://conductscience.org/api/papers/v1/39724243/references?page=2